Skip to content

Nasdaq · CIK 0001937993

CVKD Cadrenal Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing Jun 26, 2026. Close $0.91 on Oct 9, 2026, 0% from the 52-week low and -94% from the high.

Cadrenal Therapeutics, Inc. (CVKD) has 31 SEC Form 4 filings on file from 6 insiders, the latest filed on Jun 26, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

22 open-market trades have been scored at CVKD. The newest: Quang X Pham (Chairman, CEO and Interim CFO) sold $34k of stock on Jun 25, 2026, filed Jun 26, 2026, scored 11 (weak), under a 10b5-1 plan. The largest of the 22 shown: Matthew K Szot (Chief Financial Officer) sold $174k on Sep 24, 2025, scored 31 (weak), under a 10b5-1 plan. 2 insiders sold within 14 days of each other around Oct 24, 2025.

CVKD closed at $0.91 on Oct 9, 2026, 0% above its 52-week low and 94% below its 52-week high.

25 Form 144 notices of planned sales are on file, the latest filed Jun 15, 2026.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company

Price and insider trades, last year

CVKDOct 9, 2026 · close 0.91

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Cadrenal Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
11WeakQuang X Pham
Chairman, CEO and Interim CFO
sell
$34k
11,156 shares
-10%0% from low-80% from high
11WeakQuang X Pham
Chairman, CEO and Interim CFO
sell
$40k
11,444 shares
-9%+5% from low-78% from high
5WeakQuang X Pham
Chairman, CEO and Interim CFO
sell
$13k
4,126 shares
-3%0% from low-79% from high
18WeakQuang X Pham
Chairman, CEO and Interim CFO
sell
$70k
18,124 shares
-12%+2% from low-73% from high
20WeakQuang X Pham
Chairman, CEO and Interim CFO
sell
$93k
22,385 shares
-13%+0% from low-72% from high
11WeakQuang X Pham
CEO and Chairman
sell
$36k
8,285 shares
-5%0% from low-73% from high
5WeakQuang X Pham
CEO and Chairman
sell
$3,075
652 shares
-0%+17% from low-68% from high
13WeakQuang X Pham
CEO and Chairman
sell
$69k
12,763 shares
-7%+30% from low-65% from high
5WeakQuang X Pham
CEO and Chairman
sell
$6,629
1,165 shares
-1%+22% from low-66% from high
30WeakMatthew K Szot
Chief Financial Officer
sell
$69k
9,933 shares
-100%-
19WeakQuang X Pham
CEO and Chairman
sell
$34k
2,444 shares
-1%-
27WeakMatthew K Szot
Chief Financial Officer
sell
$50k
3,600 shares
-27%-
22WeakMatthew K Szot
Chief Financial Officer
sell
$49k
3,493 shares
-21%-
20WeakQuang X Pham
CEO and Chairman
sell
$51k
3,600 shares
-2%-
10WeakMatthew K Szot
Chief Financial Officer
sell
$1,497
107 shares
-1%-
13WeakQuang X Pham
CEO and Chairman
sell
$7,065
500 shares
-0%-
13WeakQuang X Pham
CEO and Chairman
sell
$18k
1,300 shares
-1%-
15WeakMatthew K Szot
Chief Financial Officer
sell
$25k
1,800 shares
-10%-
24WeakQuang X Pham
CEO and Chairman
sell
$132k
9,371 shares
-4%-
31WeakMatthew K Szot
Chief Financial Officer
sell
$174k
12,400 shares
-40%-
21WeakQuang X Pham
CEO and Chairman
sell
$70k
5,029 shares
-2%-
15WeakMatthew K Szot
Chief Financial Officer
sell
$28k
2,000 shares
-6%-

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Jun 15, 2026 Quang X. Pham
Officer
40,000
1.39% of outstanding
$148kJun 15, 2026$266k
May 11, 2026 Quang X. Pham
Officer
60,000
2.09% of outstanding
$349kMay 11, 2026none
Dec 29, 2025 MATTHEW K SZOT
Officer
9,933
0.48% of outstanding
$74kDec 29, 2025$125k
Oct 27, 2025 Quang X. Pham
Officer
1,315
0.06% of outstanding
$18kOct 27, 2025$294k
Oct 27, 2025 MATTHEW SZOT
Officer
1,800
0.09% of outstanding
$25kOct 27, 2025$303k
Oct 24, 2025 Quang X. Pham
Officer
1,129
0.06% of outstanding
$16kOct 24, 2025$278k
Oct 24, 2025 MATTHEW SZOT
Officer
1,800
0.09% of outstanding
$25kOct 24, 2025$278k
Oct 14, 2025 Quang X. Pham
Officer
1,800
0.09% of outstanding
$25kOct 13, 2025$252k
Oct 14, 2025 MATTHEW SZOT
Officer
1,800
0.09% of outstanding
$25kOct 13, 2025$253k
Oct 9, 2025 Quang X. Pham
Officer
1,800
0.09% of outstanding
$25kOct 9, 2025$227k
Oct 9, 2025 MATTHEW SZOT
Officer
1,693
0.08% of outstanding
$24kOct 9, 2025$229k
Oct 6, 2025 MATTHEW SZOT
Officer
107
0.01% of outstanding
$1,517Oct 6, 2025$227k
Oct 2, 2025 Quang X. Pham
Officer
500
0.02% of outstanding
$7,066Oct 2, 2025$220k
Oct 1, 2025 Quang X. Pham
Officer
881
0.04% of outstanding
$12kOct 1, 2025$208k
Oct 1, 2025 MATTHEW SZOT
Officer
1,700
0.08% of outstanding
$24kOct 1, 2025$204k
Sep 29, 2025 Quang X. Pham
Officer
419
0.02% of outstanding
$5,870Sep 29, 2025$202k
Sep 29, 2025 MATTHEW SZOT
Officer
100
0.00% of outstanding
$1,403Sep 29, 2025$202k
Sep 25, 2025 Quang X. Pham
Officer
6,790
0.33% of outstanding
$96kSep 24, 2025$106k
Sep 25, 2025 MATTHEW SZOT
Officer
10,900
0.53% of outstanding
$150kSep 25, 2025$49k
Sep 24, 2025 Quang Pham
Officer
2,581
0.13% of outstanding
$36kSep 24, 2025$70k
Sep 24, 2025 MATTHEW SZOT
Officer
1,500
0.07% of outstanding
$21kSep 24, 2025$28k
Aug 28, 2025 MATTHEW SZOT
Officer
400
0.02% of outstanding
$5,572Aug 28, 2025$22k
Aug 28, 2025 Pham Quang X
Officer
1,193
0.06% of outstanding
$17kAug 28, 2025$53k
Aug 27, 2025 MATTHEW SZOT
Officer
1,600
0.08% of outstanding
$22kAug 27, 2025none
Aug 27, 2025 Pham Quang X
Officer
30,600
1.49% of outstanding
$428kAug 27, 2025none

Transactions

The newest 50 of 53 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jun 25, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-2,127$3.00$6,381115,018Jun 26, 2026
Jun 26, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-9,029$3.05$28k105,989Jun 26, 2026
Jun 22, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-9,167$3.55$33k119,422Jun 24, 2026
Jun 23, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-2,277$3.20$7,286117,145Jun 24, 2026
Jun 16, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-3,613$3.18$11k129,102Jun 18, 2026
Jun 17, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-513$3.16$1,621128,589Jun 18, 2026
Jun 11, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-1,462$4.12$6,023149,377Jun 15, 2026
Jun 12, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-12,996$3.94$51k136,381Jun 15, 2026
Jun 15, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-3,666$3.58$13k132,715Jun 15, 2026
Jun 8, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-5,893$4.38$26k167,331Jun 10, 2026
Jun 9, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-12,992$4.06$53k154,339Jun 10, 2026
Jun 10, 2026Quang X Pham
Chairman, CEO and Interim CFO
SOpen-market sale
Common Stock10b5-1
-3,500$4.21$15k150,839Jun 10, 2026
Jun 3, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-2,323$4.26$9,896179,186Jun 5, 2026
Jun 4, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-3,898$4.41$17k175,288Jun 5, 2026
Jun 5, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-2,064$4.42$9,123173,224Jun 5, 2026
May 29, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-303$5.01$1,518181,858Jun 2, 2026
Jun 2, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-349$4.46$1,557181,509Jun 2, 2026
May 11, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-6,476$5.76$37k188,448May 29, 2026
May 12, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-3,298$5.28$17k185,150May 29, 2026
May 28, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-2,989$4.93$15k182,161May 29, 2026
May 22, 2026Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-1,165$5.69$6,629194,924May 26, 2026
Dec 29, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-9,933$6.97$69k0Dec 31, 2025
Dec 2, 2025Lee Scott Golden
director
AGrant or award
Stock Optionsderivative
+5,000$0.00$05,000Dec 3, 2025
Oct 24, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-1,129$14.03$16k197,404Oct 28, 2025
Oct 24, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-1,800$13.99$25k11,733Oct 28, 2025
Oct 27, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-1,315$13.99$18k196,089Oct 28, 2025
Oct 27, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-1,800$13.99$25k9,933Oct 28, 2025
Oct 9, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-1,693$13.99$24k15,333Oct 14, 2025
Oct 9, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-1,800$14.02$25k200,333Oct 14, 2025
Oct 13, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-1,800$14.07$25k13,533Oct 14, 2025
Oct 13, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-1,800$14.15$25k198,533Oct 14, 2025
Oct 6, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-107$13.99$1,49717,026Oct 7, 2025
Oct 2, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-500$14.13$7,065202,133Oct 3, 2025
Sep 29, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-419$14.01$5,870203,514Oct 1, 2025
Sep 29, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-100$14.00$1,40018,833Oct 1, 2025
Oct 1, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-881$14.01$12k202,633Oct 1, 2025
Oct 1, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-1,700$13.99$24k17,133Oct 1, 2025
Sep 24, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-2,581$13.99$36k210,723Sep 26, 2025
Sep 24, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-1,500$14.00$21k29,833Sep 26, 2025
Sep 25, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-6,790$14.09$96k203,933Sep 26, 2025
Sep 25, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-10,900$14.05$153k18,933Sep 26, 2025
Aug 27, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-3,836$13.99$54k214,497Aug 29, 2025
Aug 27, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-1,600$14.00$22k31,733Aug 29, 2025
Aug 28, 2025Quang X Pham
CEO and Chairman
SOpen-market sale
Common Stock10b5-1
-1,193$13.99$17k213,304Aug 29, 2025
Aug 28, 2025Matthew K Szot
Chief Financial Officer
SOpen-market sale
Common Stock10b5-1
-400$14.00$5,60031,333Aug 29, 2025
Feb 5, 2025James J. Ferguson III
Chief Medical Officer
AGrant or award
Stock Optionsderivative
+60,000$0.00$060,000Feb 6, 2025
Jan 23, 2025Robert Lisicki
director
AGrant or award
Stock Optionsderivative
+20,000$0.00$020,000Jan 24, 2025
Jan 23, 2025Quang X Pham
CEO and Chairman
AGrant or award
Stock Optionsderivative
+65,000$0.00$065,000Jan 24, 2025
Jan 23, 2025Matthew K Szot
Chief Financial Officer
AGrant or award
Stock Optionsderivative
+50,000$0.00$050,000Jan 24, 2025
Jan 23, 2025Jeffrey Scott Cole
Chief Operating Officer
AGrant or award
Stock Optionsderivative
+25,000$0.00$025,000Jan 24, 2025
50 of 53 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about CVKD

Answered from the filings on this page, as of the latest one.

Are insiders buying CVKD?

No. In the last 90 days no insider at Cadrenal Therapeutics, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade CVKD on the open market?

Quang X Pham (Chairman, CEO and Interim CFO) sold $34k of CVKD on Jun 25, 2026 and filed the Form 4 on Jun 26, 2026. InsiderTell scored 11 (weak), under a 10b5-1 plan.

How many insiders file Form 4 at Cadrenal Therapeutics, Inc.?

6 people have filed a Form 4 at Cadrenal Therapeutics, Inc., among them Jeffrey Scott Cole (Chief Operating Officer), James J. Ferguson III (Chief Medical Officer), Lee Scott Golden (officer and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

CVKD insider trading: Cadrenal Therapeutics, Inc. | InsiderTell